Clinica e Investigacion en Arteriosclerosis最新文献

{"title":"Utilidad de la ecografía en el cribado del aneurisma de aorta abdominal en atención primaria","authors":"Antonio López-Téllez ,&nbsp;José Manuel Ramírez Torres ,&nbsp;Estrella Pérez Vázquez ,&nbsp;Miguel Ángel Babiano Fernández ,&nbsp;Helena López-Martí ,&nbsp;Irene Zapata Martínez ,&nbsp;Cristóbal Trillo Fernández ,&nbsp;Manuel Frías Vargas ,&nbsp;María Dolores Domínguez Pinos ,&nbsp;Juan Fernando Peiró Morant ,&nbsp;José Antonio González-Fajardo ,&nbsp;Pedro Valdivielso Felices","doi":"10.1016/j.arteri.2023.12.006","DOIUrl":"10.1016/j.arteri.2023.12.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Abdominal aortic aneurysm (AAA) constitutes a pathology with high mortality. There is currently no screening program implemented in primary care in Spain.</p></div><div><h3>Objectives</h3><p>To evaluate the usefulness of ultrasound in the detection of AAA in the at-risk population in primary care. Secondarily, to identify subjects whose vascular risk (VR) should be reclassified and to determine whether AAA is associated with the presence of carotid plaque and other risk factors.</p></div><div><h3>Material and methods</h3><p>Cross-sectional, descriptive, multicenter, national, descriptive study in primary care.</p></div><div><h3>Subjects</h3><p>A consecutive selection of hypertensive males aged between 65 and 75 who are either smokers or former smokers, or individuals over the age of 50 of both sexes with a family history of AAA. Measurements: Diameter of abdominal aorta and iliac arteries; detection of abdominal aortic and carotid atherosclerotic plaque. VR was calculated at the beginning and after testing (SCORE).</p></div><div><h3>Results</h3><p>One hundred and fifty patients were analyzed (age: 68.3<!--> <!-->±<!--> <!-->5 years; 89.3% male). Baseline RV was high/very high in 55.3%. AAA was detected in 12 patients (8%; 95% <span>C</span>I: 4–12); aortic ectasia in 13 (8.7%); abdominal aortic plaque in 44% and carotid plaque in 62% of the participants. VR was reclassified in 50% of subjects. The detection of AAA or ectasia was associated with the presence of carotid plaque, current smoking and lipoprotein(a), <em>p</em> <!-->&lt;<!--> <!-->0.01.</p></div><div><h3>Conclusions</h3><p>The prevalence of AAA in patients with VR is high. Ultrasound in primary care allows detection of AAA and subclinical atherosclerosis and consequently reclassification of the VR, demonstrating its utility in screening for AAA in the at-risk population.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 4","pages":"Pages 218-226"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139730642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Riesgo trombótico asociado a COVID-19 y diabetes: ¿es PAI-1 el nexo?","authors":"José A. Páramo","doi":"10.1016/j.arteri.2024.06.001","DOIUrl":"10.1016/j.arteri.2024.06.001","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 4","pages":"Pages 227-228"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asociación de la placa de ateroma carotídea con los niveles plasmáticos de IL-18 y con polimorfismos en el gen del receptor de la IL-18 en la población mediterránea","authors":"Ana Palanca ,&nbsp;Amparo Bartual-Rodrigo ,&nbsp;Carolina Cuenca ,&nbsp;Oscar D. Mayo-López ,&nbsp;Francisco Javier Ampudia-Blasco ,&nbsp;Herminia González-Navarro ,&nbsp;Juan F. Ascaso ,&nbsp;Ana Bárbara García-García ,&nbsp;Felipe Javier Chaves ,&nbsp;José T. Real ,&nbsp;Sergio Martínez-Hervás","doi":"10.1016/j.arteri.2023.12.005","DOIUrl":"10.1016/j.arteri.2023.12.005","url":null,"abstract":"<div><h3>Background</h3><p>Atherosclerosis is an inflammatory disease. Interleukin 18 (IL-18) is an inflammatory molecule that has been linked to the development of atherosclerosis and cardiovascular disease.</p></div><div><h3>Objective</h3><p>To evaluate the possible relationship between plasma levels of IL-18 and the presence of atherosclerosis evaluated at the carotid level, as well as to analyze the possible modulation by different polymorphisms in a Mediterranean population.</p></div><div><h3>Material and methods</h3><p>Seven hundred and forty-six individuals from the metropolitan area of Valencia were included, recruited over a period of 2 years. Hydrocarbon and lipid metabolism parameters were determined using standard methodology and IL-18 using ELISA. In addition, carotid ultrasound was performed and the genotype of four SNPs related to the IL-18 signaling pathway was analyzed.</p></div><div><h3>Results</h3><p>Patients with higher plasma levels of IL-18 had other associated cardiovascular risk factors. Elevated IL-18 levels were significantly associated with higher carotid IMT and the presence of atheromatous plaques. The genotype with the A allele of the SNP rs2287037 was associated with a higher prevalence of carotid atheromatous plaque. On the contrary, the genotype with the C allele of the SNP rs2293224 was associated with a lower prevalence of atheromatous plaque.</p></div><div><h3>Conclusions</h3><p>High levels of IL-18 were significantly associated with a higher carotid IMT and the presence of atheromatous plaques, which appear to be influenced by genetic factors, as evidenced by associations between SNPs in the IL-18 receptor gene and the presence of atheroma plaque.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 4","pages":"Pages 210-217"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139433087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prof. Rafael Carmena Rodríguez","authors":"Juan F Ascaso","doi":"10.1016/j.arteri.2024.06.003","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.06.003","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 4","pages":"Pages 267-268"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916824000470/pdfft?md5=6630edd5e6f1ce1259d5d554e497d908&pid=1-s2.0-S0214916824000470-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141595882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombotic risk assessed by PAI-1 in patients with COVID-19: The influence of hyperglycemia and diabetes mellitus","authors":"Lourdes Basurto ,&nbsp;Leticia Manuel-Apolinar ,&nbsp;Ariadna Robledo ,&nbsp;Sean O’Leary ,&nbsp;Carlos Martínez-Murillo ,&nbsp;Lina Ivette Medina-Ortíz ,&nbsp;Mario German Montes Osorio ,&nbsp;Julio Zarazua ,&nbsp;Lourdes Balcázar-Hernández ,&nbsp;Juan Carlos Anda-Garay","doi":"10.1016/j.arteri.2023.12.004","DOIUrl":"10.1016/j.arteri.2023.12.004","url":null,"abstract":"<div><h3>Objective</h3><p>To assess thrombotic risk with PAI-1 levels in patients with COVID-19, to evaluate PAI-1 differences between hyperglycemic and/or Type 2 Diabetes Mellitus (T2DM) versus non-hyperglycemic patients, and to analyze the association of plasminogen activator inhibitor-1 (PAI-1) with hyperglycemia and T2DM.</p></div><div><h3>Methods</h3><p>A cross-sectional study carried out in 181 patients hospitalized for COVID-19. Two groups were formed: the patients with hyperglycemia at admission and/or previously diagnosed T2DM group and the non-hyperglycemic group. Fibrinolysis was assessed by measuring PAI-1 levels by ELISA.</p></div><div><h3>Results</h3><p>The mean age was 59.4<!--> <!-->±<!--> <!-->16.1 years; 55.8% were male 54.1% of patients presented obesity, 38.1% had pre-existing T2DM and 50.8% had admission hyperglycemia and/or pre-existing T2DM. The patients with admission hyperglycemia and/or preexisting T2DM had higher PAI-1 compared with non-hyperglycemic patients [197.5 (128.8–315.9) vs 158.1 (113.4–201.4) ng/mL; <em>p</em> <!-->=<!--> <!-->0.031]. The glucose levels showed a positive correlation with PAI-1 levels (<em>r</em> <!-->=<!--> <!-->0.284, <em>p</em> <!-->=<!--> <!-->0.041). A multivariate logistic regression analysis showed association of PAI-1 level and hyperglycemia and pre-existing T2DM with severity of COVID-19.</p></div><div><h3>Conclusion</h3><p>Patients hospitalized for COVID-19 infection with preexisting T2DM or hyperglycemia detected during their hospitalization presented a greater increase in PAI-1 levels, which suggests that hyperglycemia contributes directly to the hypercoagulable state and probably a worse outcome from the patients.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 4","pages":"Pages 201-209"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916823001195/pdfft?md5=86b08e9724c54f8fed9aa1ddc260273c&pid=1-s2.0-S0214916823001195-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139433090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consenso sobre lipoproteína (a) de la Sociedad Española de Arteriosclerosis. Revisión bibliográfica y recomendaciones para la práctica clínica","authors":"Javier Delgado-Lista ,&nbsp;Jose M. Mostaza ,&nbsp;Teresa Arrobas-Velilla ,&nbsp;Francisco Blanco-Vaca ,&nbsp;Luis Masana ,&nbsp;Juan Pedro-Botet ,&nbsp;Pablo Perez-Martinez ,&nbsp;Fernando Civeira ,&nbsp;Jose I. Cuende-Melero ,&nbsp;Jose J. Gomez-Barrado ,&nbsp;Carlos Lahoz ,&nbsp;Xavier Pintó ,&nbsp;Manuel Suarez-Tembra ,&nbsp;Jose Lopez-Miranda ,&nbsp;Carlos Guijarro","doi":"10.1016/j.arteri.2024.03.002","DOIUrl":"10.1016/j.arteri.2024.03.002","url":null,"abstract":"<div><p>The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a).</p><p>However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a).</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 4","pages":"Pages 243-266"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916824000238/pdfft?md5=76435180d7cbcd8d281b2b14c374f51e&pid=1-s2.0-S0214916824000238-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Análisis clínico-epidemiológico de pacientes con lipoproteína(a) elevada en un hospital de tercer nivel","authors":"Manuel García de Prada ,&nbsp;Ramón Costa Segovia ,&nbsp;Marta de Castro Martínez ,&nbsp;Nuria Valdeolivas Hidalgo ,&nbsp;María Belén Sánchez López ,&nbsp;Agustín Blanco Echevarría","doi":"10.1016/j.arteri.2023.12.001","DOIUrl":"10.1016/j.arteri.2023.12.001","url":null,"abstract":"<div><h3>Objective</h3><p>The objective of the study is to describe the clinical and epidemiological characteristics of our patients with elevated Lp(a).</p></div><div><h3>Materials and methods</h3><p>A descriptive cross-sectional study was conducted on 316 patients with elevated Lp(a) (&gt;125 nmol/L) in a random sample between January and August 2022. We measured epidemiological, anthropometric, clinical and laboratory variables (lipid metabolism parameters, carbohydrates and hormones).</p></div><div><h3>Results</h3><p>Mean age of our sample subject's was 59 ± 15 years with 56% males. The average BMI was 27.6 kg/m2 (71% with elevated BMI). Elevated waist circumference was observed in 54.1% of men and 77.8% of women. 48% had hypertension, 30.7% had diabetes mellitus and 91.5% dyslipidemia. Only 39.7% of the patients had never smoked.</p><p>The mean values of total cholesterol were 158 ± 45 mg/dl, LDL was 81 ± 39 mg/dl, HDL was 53 ± 17 mg/dl, Triglycerides were 127 ± 61 mg/dl, and Lp(a) was 260 ± 129 nmol/L.</p><p>Regarding lipid lowering treatment, 89% were on statins, 68.6% on ezetimibe, and 13.7% on PCSK9 inhibitors. 177 patients (57,7%) had established cardiovascular disease (CVD), 16.3% had polyvascular disease, 11.7% had subclinical CVD, and 30.6% had no known CVD. Among patients with established CVD, 174 (98.3%) were on lipid-lowering treatment (97.2% on statins) and 86.4% were on antiplatelet therapy. The mean age of cardiovascular events was 55 ± 12 years in males and 60 ± 11 years in females. 65,1% of female and 56,2% of male patients suffered an early cardiovascular event.</p></div><div><h3>Conclusions</h3><p>Patients with elevated Lp(a) are at very high cardiovascular risk, particularly for early cardiovascular disease.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 118-125"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hipobetalipoproteinemia familiar ApoB específica en una paciente con hiperplasia suprarrenal congénita no clásica","authors":"Beatriz Ramos Bachiller ,&nbsp;Manuel Luque-Ramírez ,&nbsp;Carmen Rodríguez-Jiménez ,&nbsp;Francisco J. Arrieta Blanco","doi":"10.1016/j.arteri.2023.12.002","DOIUrl":"10.1016/j.arteri.2023.12.002","url":null,"abstract":"<div><p>Familial hypobetalipoproteinaemia is a disorder of lipid metabolism characterized by low levels of total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. ApoB-related familial hypolipoproteinemia is an autosomal condition with a codominance inheritance pattern. Non-classical congenital adrenal hyperplasia is an autosomal recessive disorder due to mutations in the <em>CYP21A2</em>, a gene encoding for the enzyme 21-hydroxylase, which results in an androgen excess production from adrenal source. We here present the case of a 25-year-old woman with NCAH showing decreased levels of total-cholesterol, low-density lipoprotein cholesterol and triglycerides. Her parent had digestive symptoms and severe hepatic steatosis with elevated liver enzymes, as well as decreased levels of total and low-density lipoprotein cholesterol. A genetic-molecular study of the proband identified a mutation in the <em>APOB</em> gene, which allowed a diagnosis of heterozygous ApoB-related hypolipoproteinaemia to be made.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 128-132"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular","authors":"José María Mostaza ,&nbsp;Xavier Pintó ,&nbsp;Pedro Armario ,&nbsp;Luis Masana ,&nbsp;José T. Real ,&nbsp;Pedro Valdivielso ,&nbsp;Teresa Arrobas-Velilla ,&nbsp;Ramón Baeza-Trinidad ,&nbsp;Pilar Calmarza ,&nbsp;Jesús Cebollada ,&nbsp;Miguel Civera-Andrés ,&nbsp;José I. Cuende Melero ,&nbsp;José L. Díaz-Díaz ,&nbsp;Javier Espíldora-Hernández ,&nbsp;Jacinto Fernández Pardo ,&nbsp;Carlos Guijarro ,&nbsp;Carles Jericó ,&nbsp;Martín Laclaustra ,&nbsp;Carlos Lahoz ,&nbsp;José López-Miranda ,&nbsp;José Puzo","doi":"10.1016/j.arteri.2024.02.001","DOIUrl":"10.1016/j.arteri.2024.02.001","url":null,"abstract":"<div><p>One of the objectives of the Spanish Society of Arteriosclerosis is to contribute to the knowledge, prevention and treatment of vascular diseases, which are the leading cause of death in Spain and entail a high degree of disability and health expenditure. Atherosclerosis is a multifactorial disease and its prevention requires a global approach that takes into account the associated risk factors. This document summarises the current evidence and includes recommendations for patients with established vascular disease or at high vascular risk: it reviews the symptoms and signs to evaluate, the laboratory and imaging procedures to request routinely or in special situations, and includes the estimation of vascular risk, diagnostic criteria for entities that are vascular risk factors, and general and specific recommendations for their treatment. Finally, it presents aspects that are not usually referenced in the literature, such as the organisation of a vascular risk consultation.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 133-194"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916824000172/pdfft?md5=39f5d9b393096f14fbc00c313221dbe1&pid=1-s2.0-S0214916824000172-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular: Un documento de consulta imprescindible”","authors":"Fernando Civeira ,&nbsp;Rosa M. Sánchez-Hernández","doi":"10.1016/j.arteri.2024.04.003","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.04.003","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 126-127"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140825833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}